BOLT BIOTHERAPEUTICS INC Share Price Today: Live Updates & Key Insights

BOLT BIOTHERAPEUTICS INC share price today is $4.56, up 4.85%. The stock opened at $4.64 against the previous close of $4.54, with an intraday high of $4.72 and low of $4.64.

BOLT BIOTHERAPEUTICS INC Share Price Chart

BOLT BIOTHERAPEUTICS INC

us-stock
To Invest in {{usstockname}}
us-stock

BOLT BIOTHERAPEUTICS INC Share Price Performance

$4.56 0.0485(4.85%) BOLT at 23 Mar 2026 12:16 PM Biotechnology
Lowest Today 4.64
Highest Today 4.72
Today’s Open 4.64
Prev. Close 4.54
52 Week High 9.66
52 Week Low 3.91
Day’s Range: Low 4.64 High 4.72
52-Week Range: Low 3.91 High 9.66
1 day return -
1 Week return +4.91
1 month return +1.29
3 month return -15.16
6 month return -18.4
1 year return +968.18
3 year return +233.33
5 year return -86.04
10 year return -

BOLT BIOTHERAPEUTICS INC Institutional Holdings

Sofinnova Ventures 7.18

Pivotal bioVenture Partners Investment Advisor LLC 4.93

Vivo Capital, LLC 3.77

TANG CAPITAL MANAGEMENT LLC 3.48

Nan Fung Group Holdings Ltd 3.04

Renaissance Technologies Corp 2.87

T3 Companies, LLC 1.98

Board of Ttees Leland Stanford Jr Univ 1.87

Pfizer Inc 1.63

NANO CAP NEW MILLENNIUM GROWTH FUND L P 1.07

Geode Capital Management, LLC 0.98

Shay Capital LLC 0.80

DRW Securities, LLC 0.64

Vanguard Group Inc 0.53

BlackRock Inc 0.51

Fidelity Extended Market Index 0.37

Vanguard Institutional Extnd Mkt Idx Tr 0.37

PGIM US Micro Cap Quant Equity 0.30

Fidelity Total Market Index 0.28

NT Ext Equity Mkt Idx Fd - L 0.26

Spartan Extended Market Index Pool F 0.16

Morgan Stanley - Brokerage Accounts 0.16

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.10

Fidelity Series Total Market Index 0.09

Blackrock Extended Mkt Fund CF 0.08

Northern Trust Extended Eq Market Idx 0.07

Spartan Total Market Index Pool G 0.07

Extended Equity Market Fund K 0.07

Tower Research Capital LLC 0.04

NT Ext Equity Mkt Idx Fd - NL 0.04

Vanguard Instl Ttl Stck Mkt Idx Tr 0.03

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.03

State St US Extended Mkt Indx NL Cl C 0.01

BNYM Mellon SL Market Completion UC1 0.01

Fidelity Nasdaq Composite Index 0.01

Extended Equity Market Fund M 0.01

SSgA U.S. Total Market Index Strategy 0.01

JPMorgan Chase & Co 0.00

Bank of America Corp 0.00

SBI Securities Co Ltd 0.00

BOLT BIOTHERAPEUTICS INC Market Status

Strong Buy: 1

Buy: 0

Hold: 3

Sell: 0

Strong Sell: 0

BOLT BIOTHERAPEUTICS INC Fundamentals

Market Cap 9.14 M

PB Ratio 0.3447

PE Ratio 0.0

Enterprise Value 4.59 M

Total Assets 56.75 M

Volume 33736

BOLT BIOTHERAPEUTICS INC Company Financials

Annual Revenue FY23:7198000 7.2M, FY22:5729000 5.7M, FY21:1260000 1.3M, FY20:231000 0.2M, FY19:215000 0.2M

Annual Profit FY23:null 0.0M, FY22:5729000 5.7M, FY21:1260000 1.3M, FY20:231000 0.2M, FY19:215000 0.2M

Annual Net worth FY23:-71291000 -71.3M, FY22:-85875000 -85.9M, FY21:-104394000 -104.4M, FY20:-72274000 -72.3M, FY19:-30005000 -30.0M

Quarterly Revenue Q3/2025:2169000 2.2M, Q2/2025:1804000 1.8M, Q1/2025:1222000 1.2M, Q3/2024:1141000 1.1M, Q2/2024:1275000 1.3M

Quarterly Profit Q3/2025:1879000 1.9M, Q2/2025:1804000 1.8M, Q1/2025:1222000 1.2M, Q3/2024:1141000 1.1M, Q2/2024:-14158000 -14.2M

Quarterly Net worth Q3/2025:-7144000 -7.1M, Q2/2025:-8561000 -8.6M, Q1/2025:-11040000 -11.0M, Q3/2024:-15176000 -15.2M, Q2/2024:-21195000 -21.2M

About BOLT BIOTHERAPEUTICS INC & investment objective

Company Information Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Organisation Biotechnology

Employees 23

Industry Biotechnology

CEO Mr. William P. Quinn

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right

BOLT BIOTHERAPEUTICS INC FAQs

What is the share price of BOLT BIOTHERAPEUTICS INC today?

The current share price of BOLT BIOTHERAPEUTICS INC is $4.56.

Can I buy BOLT BIOTHERAPEUTICS INC shares in India?

Yes, Indian investors can buy BOLT BIOTHERAPEUTICS INC shares by opening an international trading and demat account with Motilal Oswal.

How to buy BOLT BIOTHERAPEUTICS INC shares in India?

You can easily invest in BOLT BIOTHERAPEUTICS INC shares from India by:

Can I buy fractional shares of BOLT BIOTHERAPEUTICS INC?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of BOLT BIOTHERAPEUTICS INC?

BOLT BIOTHERAPEUTICS INC has a market cap of $9.14 M.

In which sector does BOLT BIOTHERAPEUTICS INC belong?

BOLT BIOTHERAPEUTICS INC operates in the Biotechnology sector.

What documents are required to invest in BOLT BIOTHERAPEUTICS INC stocks?

To invest, you typically need:

What is the PE and PB ratio of BOLT BIOTHERAPEUTICS INC?

The PE ratio of BOLT BIOTHERAPEUTICS INC is N/A and the PB ratio is 0.34.